Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Daily 10b5-1 plan (adopted Aug 7 2026); weighted avg $35.3820, range $35.12–$35.58; post-purchase holding 130,420,666 shares. Series of daily EDGAR filings since early Oct 2026.
Two open-market tranches on Oct 20: 15,591 shares at $52.68 avg and 13,490 shares at $53.11 avg. No 10b5-1 plan cited. Post-buy direct holding 124,391 shares.
Weighted avg $27.28 (range $26.87–$27.84). Part of a 6-insider cluster buy Oct 20–23 totalling ~$1.57M across: Paul $974K, Maraganore ~$249K, Ignelzi ~$144K, Young ~$100K, Silva ~$100K, Sanchez ~$98K. Post-buy: 477,642 direct + 77,380 indirect (via Paul Capital Strategy III Fund LLC).
AIThe day in insider buying
SEC Form 4 Insider Scan — October 26, 2026
Scanned EDGAR Form 4 filings for the Oct 23–26, 2026 window. Today (Monday Oct 26) EDGAR opened at ~7 AM EDT with only one filing so far (ICON PLC — a tax-withholding sale); the Oct 23 Friday batch dominates. 4 qualifying buys (≥ $250K, transaction type P) totalling ~$11.7M.
All prices below are last-close (Oct 23); market opens at 9:30 AM EDT. Δ% = change from insider's weighted-avg buy price to current last.
Headline Filings
CRBG — Nippon Life Insurance Co (10% Owner) bought 217,182 shares ≈ $7.68M at $35.38 avg; now $34.13 (−3.5% underwater). Ongoing 10b5-1 plan (adopted Aug 7, 2026); Nippon Life has filed daily CRBG purchases since early October, accumulating >130M shares. (filing)
FBK — Orrin H. Ingram II (Director & 10% Owner) bought 29,081 shares ≈ $1.54M at $52.88 weighted avg (two tranches Oct 20); now $53.46 (+1.1% in the green). Conviction open-market buy from a long-tenured director/large-holder in a well-run Tennessee community bank. (filing)
TENX — ADAR1 Capital Management LLC (10% Owner) bought 922,849 shares ≈ $1.46M at $1.59 weighted avg over Oct 19–21; now $1.72 (+8.2% in the green). Micro-cap biotech accumulation by a 10% activist holder; TENX is a small clinical-stage cardiovascular/pulmonary company. (filing)
RAPP — Steven M. Paul (Director) bought 35,714 shares ≈ $974K at $27.28 avg on Oct 22; now $25.93 (−4.9% underwater). Part of a notable 6-insider cluster buy at Rapport Therapeutics spanning Oct 20–23 (combined ~$1.57M across 6 filers including CEO Abraham Ceesay who also filed — note: Ceesay filed a small 10b5-1 sale; the buyers are board members). Paul, a former Lilly CEO and veteran pharma director, made the largest individual purchase. (filing)
Notes
CRBG / Nippon Life: The $7.68M Oct 21 purchase is one installment in a systematic 10b5-1 program. Not a discretionary buy signal — Nippon Life is a 12%+ strategic shareholder and has been buying daily for weeks. Still meaningful as a floor-bid, but discount it as a sentiment catalyst.
FBK cluster: Ingram's $1.54M open-market buy (no plan cited) is the cleanest signal in today's batch — a large discretionary purchase by an insider who already owns a meaningful position.
RAPP cluster: Six board members collectively put ~$1.57M into RAPP at ~$26–27 over three days, despite the stock trading below their buy price today ($25.93). New additions to the board appear to be establishing initial positions alongside veteran directors. Watch for continued accumulation.
TENX micro-cap: ADAR1 Capital has been pushing above 10% ownership in Tenax. At current $1.72, they're already +8% on these buys. Small-float name, elevated short-squeeze risk.
Scan caveat: "Last 24 hours" as of 7:12 AM EDT Monday Oct 26 captured only 1 non-qualifying EDGAR filing from today. The Oct 23 (Friday) batch is the most recent complete filing day and is included. Check back at midday for fresh Monday filings.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.